ARCUTIS BIOTHERAPEUTICS, INC. Investment Income, Interest
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Investment Income, Interest of $2.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $2.28M, a 9.78% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. investment income, interest for the quarter ending 2025-06-30 was $2.08M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month |
|---|---|---|
| 2026-06-30 | $2.28M 10-Q · filed 2026-08-05 | $4.55M 10-Q · filed 2026-08-05 |
| 2025-06-30 | $2.08M 10-Q · filed 2026-08-05 | $4.61M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |